Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the N-terminus
The protein has a calculated MW of 25.5 kDa. The protein migrates as 34-46 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus CLEC12A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
Anti-CLL1 CAR-T (Guangzhou Bio-Gene) | BG-1805; BG1805 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
Anti-CLL1 CAR T cell therapy(Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details | |
ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
DCLL-9718S | DCLL-9718S; MCLL-0517A; RG-6109 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital) | Phase 1 Clinical | Shanghai Jiao Tong University Affiliated First People'S Hospital | Leukemia, Myeloid, Acute | Details | |
CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) | Phase 1 Clinical | Zhejiang University, Hangzhou Qihan Jiyin Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
CD371-YSNVZ-IL18 CAR T cells therapy | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Myeloid, Acute | Details | |
CLL-1/CD33 Targeted LCAR-AMDR Cells(Nanjing Legend Biotechnology) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
CLL1 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
CLL1 CAR T-cell Therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
KITE-222 | Phase 1 Clinical | Kite Pharma | Leukemia, Myeloid, Acute | Details | |
Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.